Selection of Sample for Review. For each IRO Reporting Period, the OIG shall have the discretion to identify up to 50 physicians or Related Entities from the applicable Physician Payment Listing that will be subject to the IRO review described below. If the OIG elects to exercise this discretion, it shall notify the IRO at least 90 days prior to the end of the IRO Reporting Period, of the physicians and/or Related Entities subject to the IRO review. If the OIG elects not to exercise its discretion as described above, the IRO shall randomly select 50 physicians and/or Related Entities to be included in the review. For each selected physician and/or Related Entity, the IRO shall review the entry in the Physician Payment Listing and the Control Documents relating to Payments reflected in the Listing identified by the IRO as necessary and sufficient to validate the Payment information in the Listing.
Selection of Sample for Review. For each Reporting Period, the OIG shall have the discretion to identify up to 50 physicians or Related Entities from the applicable Physician Payment Listing that will be subject to the IRO review described below. If the OIG elects to exercise this discretion, it shall notify the IRO of the physicians and/or Related Entities subject to the IRO review. If the OIG elects not to exercise its discretion as described above, the IRO shall randomly select 50 physicians and/or Related Entities to be included in the review. For each selected physician and/or Related Entity, the IRO shall review the entry in the Physician Payment Listing and the Control Documents relating to Payments reflected in Listing identified by the IRO as necessary and sufficient to validate the Payment information in the Listing. Appendix B Xxx Xxxxx, Inc. CIA
Selection of Sample for Review. For each Reporting Period, the OIG shall have the discretion to identify up to 50 Covered Recipients who received Payments from Avanir during the prior calendar year who will be subject to the review described below. If the OIG elects to exercise this discretion, it shall notify the IRO at least 90 days prior to the end of the Reporting Period of the Covered Recipients subject to the IRO review. If the OIG elects not to exercise its discretion as described above, the IRO shall randomly select 50 Covered Recipients to be included in the review. For each selected Covered Recipient, the IRO shall review Control Documents relating to Payments to the Covered Recipient for all categories reflected on the Open Payments Data website, except for the Food/Beverage and Travel/Lodging categories of Payments.
Selection of Sample for Review. For each Reporting Period, the OIG shall have the discretion to identify up to 50 Physician Covered Recipients from the applicable report that will be subject to the IRO review described below. If the OIG elects to exercise this discretion, it shall notify the IRO of the Physician Covered Recipients subject to the IRO review. If the OIG elects not to exercise its discretion as described above, the IRO shall randomly select 50 Physician Covered Recipients to be included in the review. For each selected Physician Covered Recipient, the IRO shall review the entry in the report and the Control Documents relating to Payments reflected in the report identified by the IRO as necessary and sufficient to validate the Payment information in the report.
Selection of Sample for Review. For each Reporting Period, the OIG shall have the discretion to identify up to 50 Covered Recipients who received Payments from Insys during the prior calendar year who will be subject to the review described
Selection of Sample for Review. For each Reporting Period, the OIG shall have the discretion to identify at least 10 percent but no more than 40 physicians or Related Entities from the applicable Physician Payment Listing that will be subject to the IRO review described below. If the OIG elects to exercise this discretion, it shall notify the IRO, at least 90 days prior to the end of the Reporting Period, of the physicians and/or Related Entities subject to the IRO review. If the OIG elects not to exercise its discretion as described above, the IRO shall randomly select at least 10 percent but no more than 40 physicians and/or Related Entities to be included in the review. For each selected physician and/or Related Entity, the IRO shall review the entry in the Physician Payment Listing and the Control Documents relating to Payments reflected in Listing identified by the IRO as necessary and sufficient to validate the Payment information in the Listing.
Selection of Sample for Review. For each Reporting Period, the OIG shall have the discretion to identify up to 75 U.S.-based physicians, U.S.-based Related Entities, and/or U.S.-based Product Decision-Makers from the applicable Listing that will be subject to the IRO review described below. Biovail may submit a written request to the OIG that the sample size should be less than 75 and the OIG shall decide, in its sole discretion, whether to grant the request. If the OIG elects to exercise its discretion to select the individuals or entities to be included in the review, it shall notify the IRO of the 75 identified U.S.-based physicians, U.S.-based Related Entities, and/or U.S.-based Product Decision-Makers subject to the IRO review. If the OIG elects not to exercise its discretion as described above, the IRO shall randomly select up to 75 (or such smaller number if approved by the OIG) U.S.-based physicians, U.S.-based Related Entities, and/or U.S.-based Product Decision-Makers to be included in the review. For each selected U.S.-based physician, U.S.-based Related Entity, and/or U.S.-based Product Decision-Maker, the IRO shall review the entry in the Listing and the Control Documents relating to Payments reflected in Listing identified by the IRO as necessary and sufficient to validate the Payment information in the Listing.
Selection of Sample for Review. For each IRO Reporting Period, the OIG shall have the discretion to identify at least 10 percent but no more than 50 physicians or Related Entities from the applicable Physician Payment Listing that will be subject to the IRO review described below. If the OIG elects to exercise this discretion, it shall notify the IRO at least 90 days prior to the end of the Reporting Period of the physicians and/or Related Entities subject to the IRO review. If the OIG elects not to exercise its discretion as described above, the IRO shall randomly select at least 10 percent but no more than 50 physicians and/or Related Entities to be included in the review. If Par’s Physician Payment Listing contains 10 or fewer physicians and/or Related Entities, the IRO shall consult with OIG regarding the number of physicians and/or Related Entities to review. For each selected physician and/or Related Entity, the IRO shall review the entry in the Physician Payment Listing and the Control Documents relating to Payments reflected in the Listing identified by the IRO as necessary and sufficient to validate the Payment information in the Listing.
Selection of Sample for Review. For the first Reporting Period, the IRO shall randomly select and review records relating to a sample of 250 activities in which Evaluation Product is provided to customers. For the second and subsequent Reporting Periods, the IRO shall review records relating to a total of at least 250 activities in which Evaluation Product is provided to customers.
Selection of Sample for Review. For each Reporting Period, the OIG shall have the discretion to identify up to 30 Covered Recipients who received Payments from ACell during the prior calendar year and will be subject to the IRO review described below. If the OIG elects to exercise this discretion, it shall notify the IRO of the Covered Recipients subject to the IRO review. If the OIG elects not to exercise its discretion as described above, the IRO shall randomly select 30 Covered Recipients to be included in the review.
